Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | ONCOLOGY//CELL BIOLOGY//BIOCHEMISTRY & MOLECULAR BIOLOGY | 2934640 |
196 | 3 | LUNG CANCER//NON SMALL CELL LUNG CANCER//THORAC SURG | 53631 |
2113 | 2 | CRIZOTINIB//ALK//ANAPLASTIC LYMPHOMA KINASE | 5482 |
4265 | 1 | CRIZOTINIB//ALK//ANAPLASTIC LYMPHOMA KINASE | 1850 |
11049 | 1 | EVOLUT CANC//INTRATUMOR HETEROGENEITY//CANCER EVOLUTION | 1040 |
13044 | 1 | CANCER GENOME//DRIVER GENE//PRECIS HLTH | 895 |
14602 | 1 | CONTINUAL REASSESSMENT METHOD//DOSE FINDING//DOSE FINDING STUDIES | 789 |
21842 | 1 | RESEARCH BIOPSY//PRECISION ONCOLOGY//PERSONALIZED CANC THER Y | 427 |
22325 | 1 | NCI 60//ADV BIOINFORMAT SYST MED//CLUSTERED IMAGE MAP | 409 |
38002 | 1 | SYSTEMS PATHOLOGY//ABT KLIN ONKOL RADIOTHER IE//AOVV | 72 |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | CRIZOTINIB | authKW | 1157274 | 5% | 73% | 277 |
2 | ALK | authKW | 699832 | 5% | 45% | 269 |
3 | ANAPLASTIC LYMPHOMA KINASE | authKW | 599483 | 4% | 54% | 193 |
4 | CONTINUAL REASSESSMENT METHOD | authKW | 453241 | 2% | 87% | 91 |
5 | ROS1 | authKW | 371507 | 1% | 81% | 80 |
6 | ALECTINIB | authKW | 364034 | 1% | 93% | 68 |
7 | DOSE FINDING | authKW | 352536 | 2% | 48% | 128 |
8 | EML4 ALK | authKW | 338351 | 2% | 71% | 83 |
9 | CERITINIB | authKW | 326939 | 1% | 89% | 64 |
10 | ALK INHIBITOR | authKW | 318100 | 1% | 86% | 64 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Oncology | 43179 | 46% | 0% | 2535 |
2 | Mathematical & Computational Biology | 17103 | 11% | 1% | 578 |
3 | Statistics & Probability | 4388 | 7% | 0% | 404 |
4 | Genetics & Heredity | 3365 | 11% | 0% | 630 |
5 | Respiratory System | 2898 | 7% | 0% | 360 |
6 | Medical Informatics | 2742 | 3% | 0% | 160 |
7 | Cell Biology | 1728 | 11% | 0% | 600 |
8 | Biotechnology & Applied Microbiology | 1698 | 9% | 0% | 484 |
9 | Biochemical Research Methods | 1441 | 6% | 0% | 345 |
10 | Pathology | 1263 | 5% | 0% | 267 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | EVOLUT CANC | 103935 | 1% | 41% | 44 |
2 | TRANSLAT CANC THER EUT | 48529 | 0% | 33% | 26 |
3 | TRANSLAT PL STAT | 47880 | 0% | 56% | 15 |
4 | CANC GENOME PROJECT | 44869 | 1% | 19% | 41 |
5 | PERSONALIZED CANC THER Y | 41268 | 1% | 25% | 29 |
6 | MED ONCOL | 34474 | 10% | 1% | 551 |
7 | INVEST CANC THER EUT | 32554 | 1% | 12% | 47 |
8 | CREEC | 29555 | 0% | 86% | 6 |
9 | PATHOL PROJECT MOL TARGETS | 28272 | 0% | 31% | 16 |
10 | CRUK LUNG CANC EXCELLENCE | 22981 | 0% | 50% | 8 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | JOURNAL OF THORACIC ONCOLOGY | 57677 | 3% | 6% | 167 |
2 | LUNG CANCER | 19194 | 2% | 3% | 124 |
3 | STATISTICS IN MEDICINE | 13426 | 2% | 2% | 132 |
4 | CANCER DISCOVERY | 11258 | 1% | 6% | 32 |
5 | NATURE REVIEWS CLINICAL ONCOLOGY | 10186 | 1% | 6% | 29 |
6 | GENOME MEDICINE | 9346 | 1% | 5% | 34 |
7 | PHARMACEUTICAL STATISTICS | 8847 | 1% | 5% | 29 |
8 | CLINICAL CANCER RESEARCH | 8458 | 3% | 1% | 152 |
9 | ONCOTARGET | 7191 | 3% | 1% | 145 |
10 | GENOME BIOLOGY | 6144 | 1% | 2% | 58 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CRIZOTINIB | 1157274 | 5% | 73% | 277 | Search CRIZOTINIB | Search CRIZOTINIB |
2 | ALK | 699832 | 5% | 45% | 269 | Search ALK | Search ALK |
3 | ANAPLASTIC LYMPHOMA KINASE | 599483 | 4% | 54% | 193 | Search ANAPLASTIC+LYMPHOMA+KINASE | Search ANAPLASTIC+LYMPHOMA+KINASE |
4 | CONTINUAL REASSESSMENT METHOD | 453241 | 2% | 87% | 91 | Search CONTINUAL+REASSESSMENT+METHOD | Search CONTINUAL+REASSESSMENT+METHOD |
5 | ROS1 | 371507 | 1% | 81% | 80 | Search ROS1 | Search ROS1 |
6 | ALECTINIB | 364034 | 1% | 93% | 68 | Search ALECTINIB | Search ALECTINIB |
7 | DOSE FINDING | 352536 | 2% | 48% | 128 | Search DOSE+FINDING | Search DOSE+FINDING |
8 | EML4 ALK | 338351 | 2% | 71% | 83 | Search EML4+ALK | Search EML4+ALK |
9 | CERITINIB | 326939 | 1% | 89% | 64 | Search CERITINIB | Search CERITINIB |
10 | ALK INHIBITOR | 318100 | 1% | 86% | 64 | Search ALK+INHIBITOR | Search ALK+INHIBITOR |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 2 |